These inhibitors should be evaluated for their competition with PWWP interacting partners (e.g., H3K36me2/3, splicing factors, DNA repair proteins) or IBD partners (e.g., Menin, MLL1, JPO2) and their anti-cancer activities (e.g., inhibition of cell proliferation, survival, clonogenicity, migration, invasion, tumor growth, DNA repair, and resistance to therapy) in pre-clinical models of human cancers. Here, CDCA7L is linked to cancer.